Eterna Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Eterna Therapeutics generated cash of -$20,408,000, which is more than the previous year. Cash used in financing activities reached the amount of $16,556,000 last year. Net change in cash is therefore -$3,871,000.
Cash Flow
| 2015 | -4.17M | -1.62M | 1.98M |
|---|---|---|---|
| 2017 | 549K | -1.45M | -1.46M |
| 2019 | 2.74M | -1.06M | -1.09M |
| 2020 | -8.10M | -39K | 4.66M |
| 2021 | -23.48M | -22.74M | 61.58M |
| 2022 | -20.97M | -47K | 19.57M |
| 2023 | -20.40M | -19K | 16.55M |
ERNA Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 15.54M | 16.98M | 1.63M | 5.10M | 2.58M | 5.68M | 7.04M |
Operating activities | |||||||
Net income | -21.66M | -24.57M | -122.30M | -7.29M | -2.04M | -1.07M | -7.22M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.12M | 497K | 459K | 98K | 3.16M | 2.31M | 3.10M |
Stock-based compensation expense | 1.24M | 2.93M | 5.23M | 91K | 0 | 0 | 0 |
| Deferred income tax benefit | 1.24M | 2.93M | 5.23M | 91K | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 527K | -262K | -659K | 1.67M | -248K | 142K | 1.25M |
Inventories | 0 | 262K | 485K | 52K | 337K | -3.93M | 0 |
Accounts payable | -2.89M | 2.03M | -485K | -1.73M | 669K | -586K | -372K |
Cash generated by operating activities | -20.40M | -20.97M | -23.48M | -8.10M | 2.74M | 549K | -4.17M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -19K | -297K | -154K | -39K | -1.09M | -1.45M | -1.63M |
Acquisitions Net | 0 | 250K | -22.70M | 0 | 29K | 0 | 9K |
Cash generated by investing activities | -19K | -47K | -22.74M | -39K | -1.06M | -1.45M | -1.62M |
Financing activities | |||||||
Common Stock Issued | 320K | 19.70M | 62.53M | 4.35M | 0 | 1.77M | 0 |
Payments for dividends | -16K | -16K | -8K | 0 | -16K | -16K | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 16.50M | -2K | -942K | -310K | 0 | -3.22M | 0 |
Cash used in financing activities | 16.55M | 19.57M | 61.58M | 4.66M | -1.09M | -1.46M | 1.98M |
Net Change In Cash | -3.87M | -1.44M | 15.35M | -3.47M | 673K | -2.30M | -3.82M |
Cash at end of period | 11.67M | 15.54M | 16.98M | 1.63M | 3.25M | 3.37M | 3.22M |
| Data source | Data source |